Semaglutide 15mg

Semaglutide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA). It is a modified version of the human GLP-1 hormone, which is involved in glucose regulation and appetite control.

Benefits of Semaglutide:

Semaglutide has been extensively studied and FDA-approved for the treatment of type 2 diabetes and obesity. Its benefits are well-documented in large-scale clinical trials such as STEP, SUSTAIN, and PIONEER.

1. Weight Loss

• Promotes significant and sustained weight loss by reducing appetite, delaying gastric emptying, and improving satiety.
• For chronic weight management in adults with obesity or overweight with comorbidities.
• Average weight loss: 15–20% of body weight over 68 weeks (STEP 1 trial).

2. Glycemic Control

• Improves fasting and postprandial glucose levels by stimulating insulin secretion (glucose-dependent) and suppressing glucagon.
• Reduces HbA1c by ~1.0–1.5% in type 2 diabetics (SUSTAIN trials).

3. Cardiovascular Benefits

• Reduces risk of major adverse cardiovascular events (MACE) including heart attack and stroke in high-risk patients (SUSTAIN-6 trial).

4. Appetite Regulation

• Acts on GLP-1 receptors in the hypothalamus to suppress appetite and reduce food cravings, particularly for high-fat/high-sugar foods.

5. Potential Neuroprotective and Anti-inflammatory Effects (emerging research)

• Preclinical studies suggest possible cognitive and neuroprotective benefits, though more human data are needed.

Sample Cycle or Dosage Protocol:

Semaglutide is typically administered once weekly via subcutaneous injection, and dosage should be titrated gradually to minimize gastrointestinal side effects.

For Weight Loss 

• Week 1–4: 0.25 mg once weekly
• Week 5–8: 0.5 mg once weekly
• Week 9–12: 1.0 mg once weekly
• Week 13–16: 1.7 mg once weekly
• Week 17 and onward (maintenance): 2.4 mg once weekly

Important Considerations:

• Administration: Subcutaneous injection in the abdomen, thigh, or upper arm; rotate sites weekly.
• Common side effects: Nausea, vomiting, diarrhea, constipation, fatigue, and abdominal discomfort.
• Contraindications: Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• Monitoring: Weight, blood glucose (for diabetics), gastrointestinal symptoms, and kidney function (especially in patients with existing renal impairment)